Showing 1491-1500 of 1614 results for "".
- Alcon Announces European Launch of Vivity Presbyopia-Correcting IOL With X-WAVE Technologyhttps://modernod.com/news/alcon-announces-european-launch-of-vivity-presbyopia-correcting-iol-with-x-wave-technology/2477377/Alcon announced that the AcrySof IQ Vivity IOL is now commercially available in select European markets, with additional countries to follow throughout 2020. The latest innovation in Alcon’s portfolio of presbyopia-correcting IOLs (PC-IOLs), Vivity is the first-of-its-kind, extended range
- Analysts Give Gilead’s Remdesivir 50% Chance of Success as COVID-19 Treatmenthttps://modernod.com/news/analysts-give-gileads-remdesivir-50-chance-of-success-as-covid-19-treatment/2477362/Analysts at RBC Capital Markets suggested that it is a toss-up whether Gilead Sciences’ remdesivir will succeed in demonstrating efficacy and ultimately securing approval to treat COVID-19, citing limited dosing results, confounding data and previous disappointments in Ebola. “[The] b
- Two Chicago Ophthalmology Practices Receive Strategic Investment From MoonSail Capital And Plenary Partnershttps://modernod.com/news/two-chicago-ophthalmology-practices-receive-strategic-investment-from-moonsail-capital-and-plenary-partners/2477329/Chicago Eye Institute and Arbor Centers for EyeCare, two ophthalmology practices serving the Chicago market, announced that they have entered into a strategic partnership with private investment firms MoonSail Capital and Plenary Partners to form Ocular Partners.<
- Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Dayhttps://modernod.com/news/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at-2020-research-development-day/2477322/Aldeyra Therapeutics on Monday hosted the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical development updates and market opportun
- FDA Approves CooperVision Biofinity Toric Multifocal Contact Lenseshttps://modernod.com/news/fda-approves-coopervision-biofinity-toric-multifocal-contact-lenses/2477277/The FDA has granted CooperVision approval for its new Biofinity toric multifocal contact lenses. The product combines the optical designs of CooperVision’s Biofinity toric—the most prescribed toric lens on the market1—and Biofinity multifocal to provide patients with astigmatism and pr
- Alexander van der Mey Named New CCO at Optimo Medical AGhttps://modernod.com/news/alexander-van-der-mey-named-new-cco-at-optimo-medical-ag/2477248/As of January 16, Alexander van der Mey assumed the role of chief commercial officer (CCO) position of Optimo Medical AG. In his new position, Mr. van der Mey is responsible for global marketing and sales. Mr. Van der Mey has studied business administration in Germany and the Netherlands.
- Aerie Pharmaceuticals Announces FDA Approval of its Athlone, Ireland Facility for Production of Rocklatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-fda-approval-of-its-athlone-ireland-facility-for-production-of-rocklatan/2477245/Aerie Pharmaceuticals announced that its sterile fill production facility in Athlone, Ireland has received approval from FDA to produce Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the U.S. market. The regulatory clearance of the plant follows a successful preapprov
- Hoya Surgical Optics Launches Joint Venture With GeMax in Chinahttps://modernod.com/news/hoya-surgical-optics-launches-joint-venture-with-gemax-in-china/2477238/Hoya Surgical Optics (HSO) announced a new joint venture with GeMax, a specialty promotion service provider of IOLs with a strong market position and reputation in China, covering more than 630 major hospitals in 32 provinces. The joint venture will be named Hoya GeMax Medical. HSO will be the ma
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of
- CRST: 2019 Year in Focushttps://modernod.com/news/2019-year-in-focus/2477197/Fueled by an influx of investment capital in recent years and a streamlined regulatory review process, the number of ophthalmic products approved or introduced in 2019 continued to rise steadily throughout the year. According to recent figures from pharmaceutical market research company Strategic